Angle PLC Notice of Results (4781B)
10 January 2018 - 9:16PM
UK Regulatory
TIDMAGL
RNS Number : 4781B
Angle PLC
10 January 2018
For Immediate Release 10 January 2018
ANGLE plc
("ANGLE" or "the Company")
Notification of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, will be releasing its interim results for the six months
ended 31 October 2017 on Wednesday 31 January 2018.
A meeting for analysts will be held at 10.30am on 31 January
2018 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London EC1A 4HD.
A live webcast of the analyst meeting will also be available on
ANGLE's Investor Centre page,
http://www.angleplc.com/investor-information/investor-centre/.
Please log on to the web address approximately 5 minutes before
10.30 am on the day of the results.
A recording of the webcast will also be made available on
ANGLE's website, www.ANGLEplc.com, following the results
meeting.
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is based on a patented flow through array technology. It
provides for highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry allows for the capture and amplification of over 100
biomarkers simultaneously in a single reaction. These technologies
can be combined to provide fully automated, sample to answer
results in both centralized laboratory and point of use cartridge
formats. It is ideal for measuring gene expression and other
markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future. ANGLE biomarker analysis platforms are adaptable to measure
protein and nucleic acid biomarkers across the full spectrum of
disease applications.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBGGDBGGBBGIG
(END) Dow Jones Newswires
January 10, 2018 05:16 ET (10:16 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024